Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10706482 | 0.78 | LMNA (0.33) | LMNASIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL27900531 | 0.77 | FAAH (0.41) | LMNAMEN1KMT2A | |
| SCHEMBL27900529 | 0.77 | HTR3E (0.42) | LMNASIGMAR1MEN1KMT2AHTR3E | |
| SCHEMBL27883040 | 0.73 | ALDH1A1 (0.47) | SIGMAR1MEN1KMT2AHTR3EHTR3B | |
| SCHEMBL27827544 | 0.72 | HTR7 (0.42) | — | |
| SCHEMBL27900527 | 0.70 | RXRA (0.39) | LMNAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL27883050 | 0.70 | ADRB1 (0.41) | LMNAMEN1NPC1KMT2AADRB1 | |
| SCHEMBL1406399 | 0.67 | — | — | |
| SCHEMBL27883037 | 0.66 | KAT2B (0.40) | LMNAMEN1KMT2A | |
| SCHEMBL8376402 | 0.64 | SIGMAR1 (0.43) | LMNASIGMAR1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584717-B2 | MIF modulators | YALE UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| US-20200377457-A1 | MIF MODULATORS | UNIV YALE (US) | 2020-12-03 | — | — | US | disclosed |
| US-20190270706-A1 | MIF MODULATORS | UNIV YALE (US) | 2019-09-05 | — | — | US | disclosed |
| US-10202343-B2 | MIF modulators | YALE UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180162813-A1 | MIF MODULATORS | YALE UNIVERSITY | 2018-06-14 | — | — | US | disclosed |
| US-9643922-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-9540322-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-01-10 | — | — | US | disclosed |
| US-20120040974-A1 | MIF MODULATORS | YALE UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120004261-A1 | MIF MODULATORS | YALE UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011140202-A2 | MIF MODULATORS | YALE UNIVERSITY (US) | 2011-11-10 | — | — | WO | disclosed |
| CN-102186833-A | MIF modulators | UNIV YALE | 2011-09-14 | — | — | CN | disclosed |
| EP-2326631-A2 | MIF MODULATORS | Yale University (US) | 2011-06-01 | — | — | EP | disclosed |
| CN-101932572-A | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | MERCK & CO INC | 2010-12-29 | — | — | CN | disclosed |
| US-20100267714-A1 | MIF MODULATORS | YALE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
| WO-2010021693-A2 | MIF MODULATORS | YALE UNIVERSITY (US) | 2010-02-25 | — | — | WO | disclosed |
| CN-101600706-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2009-12-09 | — | — | CN | disclosed |
| EP-1781285-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006023440-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| CN-86103464-A | The preparation method of Furobenzisoxazole derivatives | — | 1987-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584717-B2 | MIF modulators | MIF, HMGB2, HMGB3 | LMNA 4405/4885SIGMAR1 595/4885MEN1 3464/4885 |
| US-20200377457-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | LMNA 4405/4885SIGMAR1 595/4885MEN1 3464/4885 |
| US-20180162813-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | LMNA 4405/4885SIGMAR1 595/4885MEN1 3464/4885 |
| US-20120040974-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | LMNA 4405/4885SIGMAR1 595/4885MEN1 3464/4885 |
| US-20120004261-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | LMNA 4405/4885SIGMAR1 595/4885MEN1 3464/4885 |
| US-20100267714-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | LMNA 4405/4885SIGMAR1 595/4885MEN1 3464/4885 |
| US-10202343-B2 | MIF modulators | MIF, HMGB2, HMGB3 | LMNA 4405/4885SIGMAR1 595/4885MEN1 3464/4885 |
| US-20190270706-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | LMNA 4405/4885SIGMAR1 595/4885MEN1 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.